Vertex Pharmaceuticals Inc
Close on Nov 20, 2026Market cap $130.54BP/E 30.0Yield –
Vertex Pharmaceuticals Foreign currency cash flow hedge gain reclassified to by Quarter
Foreign currency cash flow hedge gain (loss) reclassified to net product revenues ($M) ($M)
Vertex Pharmaceuticals Foreign currency cash flow hedge gain reclassified to: -$10.2M in Q2 2026, down 52.1% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note (Marketable Securities, Fair Value & Derivative Instruments).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Foreign currency cash flow hedge gain (loss) reclassified to net product revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | -10.2 | -52.1% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | -25.5 | -205.8% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | -37.1 | -251.4% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | -39 | +1,158.1% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | -21.3 | -295.4% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 24.1 | +608.8% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 24.5 | -975.0% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | -3.10 | -210.7% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 10.9 | +32.9% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 3.40 | -84.5% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2023 | Dec 31, 2023 | -2.80 | -105.4% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 2.80 | -95.7% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2023 | Jun 30, 2023 | 8.20 | -81.8% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 22 | +9.5% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2022 | Dec 31, 2022 | 52.2 | +461.3% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Sep 30, 2022 | 65.2 | -1,353.8% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 45 | -355.7% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 20.1 | -221.8% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2021 | Dec 31, 2021 | 9.30 | -179.5% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2021 | Sep 30, 2021 | -5.20 | -27.8% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2021 | Jun 30, 2021 | -17.6 | -375.0% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | -16.5 | -285.4% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | -11.7 | -264.8% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2020 | Sep 30, 2020 | -7.20 | -169.9% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 6.40 | -22.0% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2020 | Mar 31, 2020 | 8.90 | +30.9% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 7.10 | +14.5% | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2019 | Sep 30, 2019 | 10.3 | +505.9% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 8.20 | -403.7% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 6.80 | -204.6% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 6.20 | – | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2018 | Sep 30, 2018 | 1.70 | – | Form 10-Q (filed 2019-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | -2.70 | – | Form 10-Q (filed 2019-08-01) ↗ |
| Q1 2018 | Mar 31, 2018 | -6.50 | – | Form 10-Q (filed 2019-05-01) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Foreign currency cash flow hedge gain reclassified to ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rev-fx-hedge-reclass
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?